Finding the Right dose for cancer therapeutics - Can we do better?

Clinical Cancer Research

Volumn 16, Issue 4, 2010, Pages 1085-1087

  Rubin, Eric H ^a   Anderson, Keaven M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; TEMSIROLIMUS;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER THERAPY; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG EFFECT; GENETIC VARIABILITY; GROWTH RATE; HUMAN; KIDNEY CANCER; MAXIMUM TOLERATED DOSE; NOTE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; VOLUMETRY; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAXIMUM TOLERATED DOSE; NEOPLASMS; TREATMENT OUTCOME;

EID: 76749125017     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3246     Document Type: Note

References (11)

1. Jain RK, Lee JJ, Hong D, et al. Phase I oncology studies: evidence that in the era of targeted therapies, patients on lower doses do not fare worse. Clin Cancer Res 2010;16:1289-97.
2. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
3. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
4. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25:209-16.
5. Zhao B, Schwartz LH, Moskowitz CS, Ginsberg MS, Rizvi NA, Kris MG. Lung cancer: computerized quantification of tumor responseinitial results. Radiology 2006;241:892-8.
6. Plathow C, Klopp M, Thieke C, et al. Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. Eur Radiol 2008;18:1635-43.
7. Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ. Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res 2009;15: 1891-7.
8. Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 2007;99:1455-61.
9. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009;27:2705-11.
10. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18.
11. Ji Y, Li Y, Nebiyou Bekele B. Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials 2007;4:235-44.